Janice Nevin
CROSS COUNTRY HEALTHCAREAbout Janice E. Nevin, M.D., MPH
Janice E. Nevin is 65, an independent director at Cross Country Healthcare (CCRN) since 2020 and President & CEO of ChristianaCare Health System (2014–present). She holds an MD from Sidney Kimmel Medical College, an MPH from the University of Pittsburgh, and a BA from Harvard; she has been recognized by Modern Healthcare as one of the 50 Most Influential Clinical Executives (2020–2022), and inducted into the Delaware Women’s Hall of Fame (2017) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| ChristianaCare Health System | President & CEO | 2014–Present | Nationally recognized leader in value-based care and population health; developed CareVio™ care coordination platform (John M. Eisenberg Patient Safety & Quality Award, 2017) |
| ChristianaCare Health System | Chief Medical Officer; Chief Patient Safety Officer | 2002–2014 | Oversight of patient safety and operations |
| Sidney Kimmel Medical College | Director | 1995–2002 | Academic leadership |
External Roles
| Organization | Role | Nature |
|---|---|---|
| ChristianaCare Health System | President & CEO | Non-profit health system executive leadership |
Board Governance
| Committee | Role | Meetings in 2024 |
|---|---|---|
| Audit Committee | Member (financial sophistication per Nasdaq Rule 5605(c)(2)(A)) | 12 |
| Governance & Nominating Committee | Member | 4 |
- Independence: The Board determined Dr. Nevin is independent under Nasdaq standards; Audit and Compensation Committees are composed entirely of independent directors .
- Board attendance and engagement: The Board met 11 times in 2024; each director attended at least 90% of Board and committee meetings for which they served, and independent directors hold executive sessions at each Board meeting. All directors attended the 2024 Annual Meeting .
- Tenure: Director since 2020; currently standing for re-election in the 2025 proxy slate .
Fixed Compensation
| Component | Amount ($) | Notes |
|---|---|---|
| Board cash retainer | 75,000 | Standard independent director retainer |
| Committee member fees | 0 | No payments for non-chair committee membership |
| Fees earned in cash (2024) | 75,000 | Reported in 2024 Director Compensation Table |
Performance Compensation
| Grant Type | Grant Date | Shares Granted | Grant Date Fair Value per Share ($) | Total Grant Date Fair Value ($) | Vesting |
|---|---|---|---|---|---|
| Restricted Stock (RSA) | June 1, 2024 | 9,921 | 15.12 | 150,000 | Vests on first anniversary of grant (one-year term) |
- Equity mix and policy: Non-employee directors received restricted stock grants targeted at ~$150,000; one-year vesting aligned with annual Board terms; stock ownership requirement set at 3x annual cash retainer, with a five-year accumulation period. As of Oct 14, 2025, all current directors are in compliance or on track .
Other Directorships & Interlocks
| Organization | Relationship to CCRN | Amount ($) | Period | Oversight |
|---|---|---|---|---|
| ChristianaCare | CCRN provided services to ChristianaCare; Dr. Nevin is President & CEO | 561,454 | Fiscal 2024 | All related party transactions reviewed and approved in advance by the Audit Committee; company discloses at $0 threshold |
Expertise & Qualifications
- Clinical executive leadership with direct experience running a large healthcare system and first-hand knowledge of healthcare staffing dynamics .
- Recognized thought leader in value-based care and population health; Modern Healthcare 50 Most Influential Clinical Executives (2020–2022) .
- Education: MD (Sidney Kimmel Medical College), MPH (University of Pittsburgh), BA (Harvard) .
- Innovation: Developed CareVio™, a data-driven care coordination platform addressing medical and social determinants of health (Eisenberg Award, 2017) .
- Financial sophistication: Identified with requisite financial sophistication for Audit Committee service under Nasdaq rules .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Outstanding | Unvested Restricted Stock | Notes |
|---|---|---|---|---|
| Janice E. Nevin, M.D., MPH | 29,936 | <1% (per table indicator) | 0 | Outstanding shares basis: 32,759,952 as of Oct 14, 2025; footnote indicates 0 restricted stock included for Dr. Nevin |
Governance Assessment
- Committee impact: Active member of the Audit Committee (12 meetings in 2024) and Governance & Nominating Committee (4 meetings), contributing to oversight of financial reporting, compliance, cybersecurity/data protection, environmental/climate risks, governance principles, succession, and Board evaluation processes .
- Independence and attendance: Classified independent under Nasdaq standards with strong engagement—at least 90% attendance at Board and committee meetings and participation in independent director executive sessions every Board meeting—supporting board effectiveness .
- Alignment: Director pay structure balances cash retainer ($75k) and annual equity (~$150k), with stock ownership guidelines (3x retainer, five-year compliance window) and full compliance/on-track status—signals alignment without excessive guaranteed pay .
- Potential conflict—managed: CCRN’s services to ChristianaCare ($561,454 in 2024) create a related-party exposure given Dr. Nevin’s CEO role; however, CCRN applies a $0 disclosure threshold and requires Audit Committee pre-approval for all related-party transactions, which were approved—mitigating but not eliminating perceived conflict risk .
- Compensation governance: The Compensation Committee engages independent consultant Pearl Meyer; no changes to director compensation for 2024/2025; anti-hedging and Dodd-Frank-compliant clawback policies exist for executives, reinforcing broader governance rigor (context for overall board compensation oversight) .
RED FLAGS: Related-party transaction with ChristianaCare where the director is CEO (requires continued robust recusal and Audit Committee oversight) . No evidence of hedging/pledging or option repricing for directors; no meeting-fee inflation; attendance metrics are solid .